Chemical Namenirmatrelvir and ritonavir
Dosage FormTablet (oral; 150 mg nirmatrelvir co-packaged with 100 mg ritonavir)
Drug ClassInhibitors
Approval Year2021


  • For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Please note that the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved Paxlovid.
Last updated on 5/2/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Paxlovid (nirmatrelvir and ritonavir) Prescribing Information.2022Pfizer Inc., New York, NY
Document TitleYearSource
Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19.2022Infectious Diseases Society of America
COVID-19 treatment guidelines.2022National Institutes of Health